Metformin as a potential combination therapy with existing front-line antibiotics for Tuberculosis

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Vashisht, Rohit ^a,b   Brahmachari, Samir K ^a,b,c  

^a ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

^b NATIONAL CHEMICAL LABORATORY   (India)

^c CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

Author keywords

Bacterial persistence; Diabeties; FDA approved drugs; Metformin; Systems biology spindle map; Tuberculosis

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL PROTEIN; METFORMIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERICIDAL ACTIVITY; DRUG BINDING SITE; DRUG EFFICACY; DRUG PROTEIN BINDING; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN SYNTHESIS INHIBITION; TUBERCULOSIS; COMBINATION DRUG THERAPY;

ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; HUMANS; METFORMIN; TUBERCULOSIS;

EID: 84924901326     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0443-y     Document Type: Article

References (8)

1. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Infect Control. 2006;34:S3-10.
2. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. Bacterial Persistence as a Phenotypic Switch. Science. 2004;305:1622-5.
3. Vashisht R, Bhat A, Kushwaha S, Bhardwaj A, Consortium O, Brahmachari S. Systems level mapping of metabolic complexity in Mycobacterium tuberculosis to identify high-value drug targets. J Transl Med. 2014;12:263.
4. Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10:143-56.
5. Yagi T, Yano T, Di Bernardo S, Matsuno-Yagi A. Procaryotic complex I (NDH-1), an overview. (BBA) - Bioenergetics. 1998;1364:125-33.
6. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998;393:537-44.
7. Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife. 2014;13(3):e02242.
8. Singhal A, Jie L, Kumar P, Hong GS, Leow MK-S, Paleja B, et al. Metformin as adjunct antituberculosis therapy. Sci Transl Med. 2014;6:263ra159.